Study of DA-9801 to Treat Diabetic Neuropathic Pain
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II dose-ranging study to evaluate the effectiveness and safety of DA-9801 in
the treatment of pain associated with diabetic neuropathy. Subjects will receive either
300mg, 600mg, 900mg or placebo, three times daily for eight weeks. During treatment, pain
score by Likert numerical rating scale, Patient Global Impression of Improvement (PGI-I) and
Change in Clinical Global Impression(CGI)are accessed to evaluate the effectiveness.
Phase:
Phase 2
Details
Lead Sponsor:
Dong-A Pharmaceutical Co., Ltd. Dong-A ST Co., Ltd.